Clinical Trial Update: Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating autoantibody reduction in acute exacerbations of idiopathic pulmonary fibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form | Phase 2 | Status: COMPLETED | Results posted: 2026-02-24